Conatus pharmaceuticals inc. (CNAT)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12
Operating activities
Net loss

-11,385

-18,010

-17,396

-29,734

-

-

-

-

Net loss

-

-

-

-

-24,148

-22,319

-15,616

-8,749

Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation

73

91

108

106

67

38

10

9

Stock-based compensation expense

4,153

3,757

4,098

3,354

3,315

2,330

257

144

Noncash other financing expense

-

-

-

-

-

-

-3,618

-91

Amortization of premiums and discounts on marketable securities, net

-204

-341

-68

5

328

577

199

-

Write off of property and equipment and other assets

210

0

0

-

-

-

-

-

Impairment of right-of-use asset

50

0

0

-

-

-

-

-

Accrued interest included in convertible note payable

0

696

658

0

0

-

-

-

Amortization of premium on marketable securities

-

-

-

-

-

-

-

-171

Changes in operating assets and liabilities:
Collaboration receivables

-3,555

310

867

2,500

0

-

-

-

Prepaid and other current assets

-642

-480

123

-935

1,185

251

469

-89

Other assets

0

537

872

624

798

62

-

-

Accounts payable and accrued expenses

-2,355

-5,760

6,638

2,856

-581

1,499

407

-91

Accrued compensation

-1,992

222

-343

918

289

-130

961

-228

Deferred revenue

-12,890

-15,099

-25,010

51,701

-

-

-

-

Lease liabilities, net

-59

0

0

-

-

-

-

-

Deferred revenue

-

-

-

-

0

-

-

-

Deferred rent

0

46

32

20

-165

-58

-

-

Net cash used in operating activities

-20,202

-34,857

-33,209

26,997

-

-

-

-

Investing activities
Net cash used in operating activities

-

-

-

-

-22,546

-18,260

-10,631

-8,564

Maturities of marketable securities

44,842

69,685

81,877

44,597

62,574

54,072

4,725

19,838

Purchase of marketable securities

15,494

39,637

121,723

40,905

58,365

29,639

53,117

10,309

Capital expenditures

11

66

25

110

88

242

3

17

Net cash provided by investing activities

29,337

29,982

-39,871

3,582

-

-

-

-

Financing activities
Proceeds from stock issuances related to exercise of stock options

-

-

-

-

-

-

-

16

Proceeds from issuance of convertible note payable, net

0

0

12,500

0

-

-

-

-

Net cash provided by (used in) investing activities

-

-

-

-

4,119

24,190

-48,396

9,511

Proceeds from issuance of convertible note payable, net

-

-

-

-

0

-

-

-

Principal payment on promissory note

0

0

1,000

0

0

-

-

-

Proceeds from issuance of common stock, net

0

0

30,610

13,522

22,305

-

58,608

-

Repurchase of common stock

0

0

11,203

0

0

-

-

-

Issuance of promissory notes

-

-

-

-

-

-

1,001

-

Distribution to wholly owned subsidiary in connection with spin-off of Idun Pharmaceuticals, Inc.

-

-

-

-

-

-

500

-

Deferred financing costs

0

118

0

0

-

264

-

-

Proceeds from stock issuances related to exercise of stock options and employee stock purchase plan

3

479

169

106

84

88

41

-

Net cash provided by financing activities

3

361

31,076

13,628

-

-

-

-

Net (decrease) increase in cash and cash equivalents

9,138

-4,514

-42,004

-

-

-

-

-

Net cash provided by financing activities

-

-

-

-

22,389

-176

59,151

16

Net increase (decrease) in cash and cash equivalents

-

-

-

44,207

3,963

5,753

122

963

Supplemental disclosure of cash flow information:
Cash paid for interest

0

0

5

70

70

70

88

70

Supplemental schedule of noncash financing activities:
Conversion of convertible note payable to common stock

0

13,729

0

0

-

-

-

-

Right-of-use asset

590

0

0

-

-

-

-

-

Purchases of property and equipment included in accounts payable

-

-

-

-

87

-

-

-

Conversion of notes payable for common stock

-

-

-

-

-

-

1,001

-

Issuance of warrants in conjunction with debt

-

-

-

-

-

-

625

-